2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonths
2013
Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey
Kim J, Ha Y, Jeong S, Kim S, Kim W, Jang T, Kim I. Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey. Prostate Cancer And Prostatic Diseases 2013, 16: 341-345. PMID: 23917307, PMCID: PMC5767467, DOI: 10.1038/pcan.2013.24.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyPatient-perceived satisfactionProstate Cancer Index Composite surveyUrinary botherEPIC scoresRadical prostatectomyIndependent factorsLongitudinal changesOverall satisfactionEPIC questionnaireProstate cancerSame patientGroup 1Optimal managementPatientsRecovery periodLinear mixed modelsProstatectomyComposite surveyMonthsDomain subscalesMenScoresMixed modelsGroup